Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme

Premium
Genzyme this week launched its cystic fibrosis gene-sequencing test. The company said the test can detect approximately 98 percent of the more than 1,200 disease-causing mutations in the CFTR gene.
 
Most genetic CF testing is performed by mutation panels, which detect the most common CFTR mutations. CF gene sequencing detects the most common mutations, as well as less common mutations not included in the available mutation panels.
 
Genzyme’s CF testing program includes CFplus, an analysis of 97 mutations that provides high CF detection rates for the pan-ethnic US population in five to eight days. This test is available on blood serum, buccal swab, and mouthwash samples.
 
CF gene sequencing offers a “more comprehensive” answer in two to three weeks, according to Genzyme, which offers physicians access to board-certified clinical molecular geneticists to discuss test results and genetic counselors for patients to discuss what testing means for them.

Filed under

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.